Ekso Bionics (NASDAQ:EKSO) Earns Hold Rating from Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note issued on Sunday. The firm set a “hold” rating on the stock.

Several other equities research analysts have also recently weighed in on EKSO. HC Wainwright lowered their price target on shares of Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th. Lake Street Capital cut their price target on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a report on Tuesday, October 29th.

Ekso Bionics Price Performance

Shares of EKSO stock opened at $0.65 on Friday. The stock has a 50 day moving average price of $0.76 and a 200 day moving average price of $0.99. Ekso Bionics has a 52-week low of $0.50 and a 52-week high of $3.13. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. The firm has a market capitalization of $14.28 million, a P/E ratio of -1.00 and a beta of 1.43.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings results on Monday, October 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. The firm had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $6.00 million. During the same quarter in the previous year, the firm posted ($0.24) EPS. As a group, sell-side analysts predict that Ekso Bionics will post -0.48 earnings per share for the current year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.